We aim to discover and develop a blood test that can predict which lung cancers have spread to lymph glands in the chest, to help decide on the best treatment options.
An Integrative Approach To Define And Attenuate Genomic Risk Of Coronary Artery Disease
Funder
National Health and Medical Research Council
Funding Amount
$988,454.00
Summary
One in four individuals that have a heart attack do not have traditional risk factors such as high blood cholesterol levels. This highlights the importance of 'family history', which we can now quantify as 'genetic risk'. These studies will determine (i) which genes are important in contributing to this genetic risk (ii) how these genes change biological pathways to increase risk and (iii) the effectiveness of modulating these biological pathways to reduce the risk of heart disease.
Strain-level Characterisation And Visualisation Of The Mucosal Microbial Communities Associated With Inflammatory Bowel Disease (IBD) For The Development Of Novel Biotherapeutics
Funder
National Health and Medical Research Council
Funding Amount
$1,181,878.00
Summary
Australia has one of the highest incidence rates in the world of Inflammatory Bowel Disease (IBD), a debilitating inflammatory condition of the gastrointestinal tract. Cutting-edge molecular and visualisation technologies will be used to examine the role of the gut microbiome in IBD, and identify specific members of this community to be used as new therapies to suppress inflammation and improve outcomes for patients with IBD.
Understanding How The E3 Ubiquitin Ligase Parkin Dictates Neuronal Survival
Funder
National Health and Medical Research Council
Funding Amount
$947,560.00
Summary
Parkinson's disease is the fastest-growing neurodegenerative disorder, and the second most common neurodegenerative disease after Alzheimer's disease. The disease arises due to the loss of specific neurons in the brain that control motor function. We aim to understand what triggers these neurons to die and to resolve how inflammation promotes disease. This information will underpin the development of the first, and much needed, drugs that slow or stop Parkinson's disease progression.
Evidence For Action On Cold, Damp And Mould In Australian Homes
Funder
National Health and Medical Research Council
Funding Amount
$955,649.00
Summary
We know that living in cold and damp homes is bad for people's health. Surprisingly in Australia we do not know how much exposure to poor conditions and financial hardship combines to generate poor health at the population level. We will quantify this impact and estimate the benefit of interventions (such as mould removal and assistance for paying utility bills). This project will provide governments with evidence for tackling this housing-related health problem.
A Practice Change For Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms: A Randomised, Controlled Intervention To Assess Efficacy And Cost-effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$1,276,080.00
Summary
Unexplained chronic gastrointestinal symptoms are extremely common and costly to the health system. Currently patients are managed in the hospital setting with the 'typical' face-to-face office-based model which sees the clinician spending valuable time gathering information and often treatments (e.g. allied health) delivered in a non-standard way. This project will evaluate the effectiveness of a new standard best-practice clinical model with a structured technology enabled management approach.
Developing Smart Nanomedicine To Enable Advanced Diagnosis And Stimuli-responsive Treatment For Atherosclerosis And Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$523,342.00
Summary
The early detection and accurate characterization of life-threatening diseases such as cardiovascular diseases are critical to the design of treatment. A therapeutic approach that provides an efficient treatment with minimal side-effects is highly desired by both patients and healthcare systems. This project aims to develop smart nanomedicine with incorporated diagnostic sensor and external stimuli-responsive treatment mechanisms for cardiovascular diseases.
Targeting A Bacterial Glyco-Achilles Heel To Make New Vaccines For Haemophilus Influenzae And Neisseria Gonorrhoeae.
Funder
National Health and Medical Research Council
Funding Amount
$526,950.00
Summary
The bacteria that cause gonorrhoea (N. gonorrhoeae), middle ear infections and exacerbations of chronic obstructive lung disease (H. influenzae) have become multi-drug resistant. These diseases are a major health and economic burden. In the absence of new drugs, a vaccine to prevent these diseases has emerged as a major unmet need in human health. In this grant, we will develop a new vaccine that targets a bacterial-specific sugar that we have discovered is the Achilles heel of these bacteria.
Targeting Pathogenic TAR DNA-binding Protein 43 To Treat Frontotemporal Dementia And Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$687,444.00
Summary
Frontotemporal dementia and motor neuron Disease are rapidly progressive and fatal neurodegenerative diseases that affect people in their prime. Poor understanding of the processes that lead to these diseases have slowed drug development. Through innovative experimental design, we aim to decipher a novel disease mechanism that involves specific molecular interactions and translate these findings into new therapies for the diseases.
Finely Tuned Glutamate Receptor Inhibitors As Novel Therapeutics For Neurodegenerative Disorders
Funder
National Health and Medical Research Council
Funding Amount
$1,168,829.00
Summary
Neurodegenerative disorders are among the leading causes of death and disease burden. New drugs are needed to treat both symptoms and disease progression. This project aims to understand the properties of different drug-like compounds to inhibit proteins on the surface of brain cells (glutamate receptors) to impact disease progression and symptoms in a preclinical disease models. The project will yield a better understanding of how best to target glutamate receptors for therapeutic effect.